Cancer drugs conferring low or no therapeutic benefits accounted for $6.7 billion in post-rebate Medicare spending in 2022.

A chatbot designed to educate cancer patients on genetic testing and help them access tests appears to be effective, according to research presented at the 50th Annual ONS Congress.

A screening program enabled timely screenings for cardiotoxicity and allowed patients to receive optimal cancer treatment.

The decision to choose systemic adjuvant therapy warrants careful discussion on its benefits and risks,” researchers wrote.

Five-year data from the KEYNOTE-048 trial support the use of pembrolizumab and pembrolizumab-chemotherapy as standards of care, researchers wrote.

(HealthDay News) — The US Food and Drug Administration (FDA) announced that it is shifting away from requiring animal testing for the development of monoclonal antibodies and other drugs and will ...